January 2, 2017
Omnitura Therapeutics will present at Biotech Showcase on January 11, 2017 in San Francisco
Omnitura Therapeutics, Inc. (Omnitura), a clinical-stage biopharmaceutical company developing first-in-class multivalent immuno-oncology therapeutics for the intervention, treatment and prevention of cancer, announced that the Company has been invited to present at the Biotech Showcase on Wednesday, January 11, 2017 at 3:15pm Pacific Time at the Hilton Union Square in San Francisco. This event takes place concurrently with the J.P. Morgan Healthcare Conference.
November 23, 2016
Omnitura Therapeutics announces new Management Team Member
Omnitura Therapeutics, Inc. (Omnitura) announced that James Levison has joined its management team as Corporate Secretary and Treasurer. Mr. Levison is a senior finance and operations executive with over forty years of experience. He is skilled in strategic and tactical financial affairs including P & L management, capital raising (public and private sector), negotiations, and treasury and cash management. Mr. Levison is highly experienced in contract management, banking relations, international operations, revenue recognition, taxation and financial reporting. Mr. Levison has previously served as Chief Financial Officer of Zephyr Photonics, Inc., Liquid Engines, Inc., and VP Finance of Think3, Inc.
“We are pleased to welcome James Levison to our management team”, said Jeffrey Dao, Co-CEO & President. “His vast experience in managing the financial planning of growth companies is an ideal match for Omnitura at this stage of our corporate development.”
May 28, 2016
Omnitura Therapeutics will present at Marcum MicroCap Conference on June 2, 2016 in New York City
Omnitura Therapeutics, Inc. (Omnitura), a clinical-stage biopharmaceutical company developing novel multivalent immune-oncology therapeutics for the intervention, treatment and prevention of cancer, announced that the Company has been invited to present at the Marcum MicroCap Conference on Thursday, June 2, 2016 at 3:00pm Easter Time at the Grand Hyatt Hotel in New York City.
November 9, 2015
Omnitura Therapeutics Announces Presentation of Aneustat™ Phase I Clinical Trial Results
Omnitura Therapeutics, Inc. (Omnitura) announced the presentation of results of the Aneustat™ (OMN54) phase I clinical trial (abstract title: "A phase 1 study of OMN54 in patients with advanced malignancies”) at the AACR-NCI-EORTC International Conference on Molecular Targets & Cancer Therapeutics on November 8, 2015 in Boston, Massachusetts. Dr. Karen Gelmon of the British Columbia Cancer Agency was the principal investigator of this clinical trial.
“This first clinical trial of Aneustat™ (OMN54) not only confirmed pre-clinical findings that Aneustat™ is well-tolerated but it also provided evidence of biological activity in cancer patients with advanced treatment-refractory disease. The results of this trial also confirmed pre-clinical research which demonstrates that Aneustat™ simultaneously regulates a number of key biological targets back to homeostatic levels. By regulating, and not blocking, biological targets, Aneustat™ provides anti-cancer effects while minimizing risk of side effects. With the findings of this clinical trial, we are now ready to proceed with phase II clinical development in a number of indications”, said James Dao, Chairman & Co-CEO.
September 10, 2015
Omnitura Therapeutics Invited to Present Aneustat™ Phase I Clinical Trial Results at AACR-NCI-EORTC Conference
Omnitura Therapeutics, Inc. (Omnitura) announced today that it has been invited to present results of the Aneustat™ (OMN54) phase I clinical trial at the AACR-NCI-EORTC International Conference on Molecular Targets & Cancer Therapeutics (Nov 5-9, 2015 in Boston).
Aneustat™ (OMN54) was designed with systems biology considerations to act on the heterogeneous cancer cells, the multiple cell types in the tumor microenvironment, and the patient’s immune/inflammatory system. Aneustat’™s activity is due to a Multifunctional Multi-targeted (MFMT) mechanism of action that overcomes the widely recognized limitations of monovalent and single-targeted drugs, including limited effectiveness, serious side effects, and the inevitable rise of drug resistance.
“Aneustat™ represents a new class of cancer therapeutics that offers new hope to cancer patients," said James Dao, Chairman and Co-CEO of Omnitura. “We are excited to share the findings of this clinical trial with the cancer research community and we welcome collaborative research projects to explore the potential of Aneustat™ to reduce suffering and mortality due to cancer."
September 1, 2015
Omnitura Therapeutics Announces the Appointment of Dr. David Wilson as Chief Operating Officer
Omnitura Therapeutics, Inc. (Omnitura) today announced the appointment of Dr. David Wilson as Chief Operating Officer. In this role, Dr. Wilson plays a leadership role in defining and implementing Omnitura's clinical development programs for its novel multivalent immuno-oncology drug candidate, Aneustat™ (OMN54).
Dr. Wilson is a senior executive with extensive domestic and international experience leading biotech/pharm corporate development, operations, product development, project and alliance management, regulatory affairs in startup and mid-size life science companies. Dr. Wilson has an an excellent track record of bringing new pharmaceutical products through different phases of research, development and commercialization, including currently marketed products such as the immuno-oncology drugs Yervoy and Opdivo. He has demonstrated successes in five biotechnology companies that have directly resulted in increased valuation and subsequent acquisition or IPO resulting in over $4B in shareholder value.
"We are very pleased by Dr. Wilson's decision to join our team," said James Dao, Chairman and Co-CEO of Omnitura. "With his product development expertise and leadership we are confident about our ability to implement innovative clinical development strategies that will accelerate the delivery of medical solutions for unmet needs in oncology.”